Dr. Anderson is the Albert H. Coons Associate Professor of Neurology at Harvard Medical School, Scientist at the Brigham and Women’s Hospital, Institute Member of the Broad Institute of MIT and Harvard, Core Faculty of the Evergrande Center for Immunologic Diseases, and Co-Chair of the Infectious and Immunologic Diseases Program at the Brigham Research Institute. She obtained her B.S. in Microbiology and Immunology in 1993 from the University of Miami, where she graduated summa cum laude. She obtained her Ph.D. in Immunology from Harvard University in 1999. During her Ph.D., she was awarded a fellowship from the Howard Hughes Medical Institute. Dr. Anderson works in the field of cancer immunology, specifically on the regulation of the anti-tumor T cell response. Her laboratory identified that the co-inhibitory molecule Tim-3 is a key regulator of T cell dysfunction in cancer and has identified gene programs associated with activated, dysfunctional, and stem-like CD8+ T cell states in cancer. Prior to working in the field of cancer immunology, Dr. Anderson worked in the field of autoimmunity. Dr. Anderson has published over 60 original papers, 19 reviews, and 5 book chapters and has been recognized as a Highly Cited Researcher in 2020,2021, and 2022 by Clarivate. Her work on T cell cross-reactivity in autoimmunity was selected by Nature Immunology as a ‘Classic Paper in Autoimmunity’ and has also had several papers selected as either ‘must-read’ or ‘recommended’ by the Faculty of 1000. Dr. Anderson is on the editorial board for OncoImmunology and The Journal for Immunotherapy of Cancer. She currently serves on the scientific advisory boards for Tizona Therapeutics, Trishula Therapeutics, Compass Therapeutics, Zumutor Biologics, ImmuneOncia, and Excepgen and is a paid consultant for iTeos Therapeutics and Larkspur Biosciences.